A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma

A global view of hepatocellular carcinoma: trends, risk, prevention and management

(2019) Ju Dong Yang et al.   Nature Reviews Gastroenterology & Hepatology

P-320Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer

(2018) K Johung et al.   ANNALS OF ONCOLOGY

Changing Trends in Etiology- and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States

(2018) Donghee Kim et al.   HEPATOLOGY

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation

(2017) David Goldberg et al.   GASTROENTEROLOGY

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

(2017) Masao Omata et al.   Hepatology International

Population attributable fractions of risk factors for hepatocellular carcinoma in the United States

(2016) Oxana V. Makarova-Rusher et al.   CANCER

Capecitabine in advanced hepatocellular carcinoma

(2016) Francesca Murer et al.   DIGESTIVE AND LIVER DISEASE

Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma

(2016) Mei Lu et al.   JOURNAL OF VIRAL HEPATITIS

The Adverse Effects of Sorafenib in Patients with Advanced Cancers

(2015) Ye Li et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Safety Surveillance of Traditional Chinese Medicine: Current and Future

(2015) Shwu-Huey Liu et al.   DRUG SAFETY

The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018)

(2015) Wing Lam et al.   BMC Complementary and Alternative Medicine

PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment

(2015) Wing Lam et al.   Scientific Reports

Preclinical studies of the Chinese Herbal Medicine formulation PHY906 (KD018) as a potential adjunct to radiation therapy

(2012) Sara Rockwell et al.   INTERNATIONAL JOURNAL OF RADIATION BIOLOGY

Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy

(2012) Shwu-Huey Liu et al.   JOURNAL OF ETHNOPHARMACOLOGY

Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment

(2011) Ena Wang et al.   BMC Medical Genomics

A Phase I Study of the Chinese Herbal Medicine PHY906 as a Modulator of Irinotecan-based Chemotherapy in Patients with Advanced Colorectal Cancer

(2011) Shivaani Kummar et al.   Clinical Colorectal Cancer

Hepatocellular carcinoma: a global view

(2010) Ju Dong Yang et al.   Nature Reviews Gastroenterology & Hepatology

Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies

(2010) M. Wasif Saif et al.   PHYTOMEDICINE

Supplements for immune enhancement in hematologic malignancies

(2009) D. M.-Y. Sze et al.   Hematology-American Society of Hematology Education Program

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

The impact of new data in the treatment of advanced hepatocellular carcinoma

(2008) Ghassan K. Abou-Alfa et al.   Current Oncology Reports